InnoCare Pharma Statistics
Total Valuation
InnoCare Pharma has a market cap or net worth of HKD 24.74 billion. The enterprise value is 18.91 billion.
Market Cap | 24.74B |
Enterprise Value | 18.91B |
Important Dates
The last earnings date was Wednesday, May 14, 2025.
Earnings Date | May 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
InnoCare Pharma has 1.76 billion shares outstanding. The number of shares has decreased by -7.72% in one year.
Current Share Class | 1.49B |
Shares Outstanding | 1.76B |
Shares Change (YoY) | -7.72% |
Shares Change (QoQ) | +11.25% |
Owned by Insiders (%) | 21.39% |
Owned by Institutions (%) | 36.03% |
Float | 1.38B |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 18.84 |
PB Ratio | 3.41 |
P/TBV Ratio | 3.56 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -62.92 |
EV / Sales | 14.40 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -60.33 |
Financial Position
The company has a current ratio of 7.84, with a Debt / Equity ratio of 0.23.
Current Ratio | 7.84 |
Quick Ratio | 7.32 |
Debt / Equity | 0.23 |
Debt / EBITDA | n/a |
Debt / FCF | -5.29 |
Interest Coverage | -9.56 |
Financial Efficiency
Return on equity (ROE) is -4.24% and return on invested capital (ROIC) is -3.19%.
Return on Equity (ROE) | -4.24% |
Return on Assets (ROA) | -2.63% |
Return on Invested Capital (ROIC) | -3.19% |
Return on Capital Employed (ROCE) | -4.79% |
Revenue Per Employee | 1.21M |
Profits Per Employee | -275,930 |
Employee Count | 1,089 |
Asset Turnover | 0.13 |
Inventory Turnover | 1.40 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +153.88% in the last 52 weeks. The beta is 0.99, so InnoCare Pharma's price volatility has been similar to the market average.
Beta (5Y) | 0.99 |
52-Week Price Change | +153.88% |
50-Day Moving Average | 9.75 |
200-Day Moving Average | 7.28 |
Relative Strength Index (RSI) | 67.36 |
Average Volume (20 Days) | 14,077,172 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoCare Pharma had revenue of HKD 1.31 billion and -300.49 million in losses. Loss per share was -0.18.
Revenue | 1.31B |
Gross Profit | 1.15B |
Operating Income | -431.94M |
Pretax Income | -311.51M |
Net Income | -300.49M |
EBITDA | -358.17M |
EBIT | -431.94M |
Loss Per Share | -0.18 |
Balance Sheet
The company has 7.51 billion in cash and 1.66 billion in debt, giving a net cash position of 5.86 billion or 3.33 per share.
Cash & Cash Equivalents | 7.51B |
Total Debt | 1.66B |
Net Cash | 5.86B |
Net Cash Per Share | 3.33 |
Equity (Book Value) | 7.25B |
Book Value Per Share | 4.03 |
Working Capital | 7.39B |
Cash Flow
In the last 12 months, operating cash flow was -241.22 million and capital expenditures -72.13 million, giving a free cash flow of -313.35 million.
Operating Cash Flow | -241.22M |
Capital Expenditures | -72.13M |
Free Cash Flow | -313.35M |
FCF Per Share | -0.18 |
Margins
Gross margin is 87.74%, with operating and profit margins of -32.89% and -22.88%.
Gross Margin | 87.74% |
Operating Margin | -32.89% |
Pretax Margin | -23.72% |
Profit Margin | -22.88% |
EBITDA Margin | -27.27% |
EBIT Margin | -32.89% |
FCF Margin | n/a |
Dividends & Yields
InnoCare Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 7.72% |
Shareholder Yield | n/a |
Earnings Yield | -1.21% |
FCF Yield | -1.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
InnoCare Pharma has an Altman Z-Score of 2.58. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.58 |
Piotroski F-Score | n/a |